Updated:
Hemex
HEMEX is an integrated Clinical Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end support for biotech, pharmaceutical, and...
Hemex
HEMEX is an integrated Clinical Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end support for biotech, pharmaceutical, and medical devices programs, from early discovery to commercial-scale manufacturing, ensuring scientific rigor and regulatory compliance. It connects every stage of development into one efficient pathway to market. Its services include Medtech, IVD, Digital Health, Pharma & Biotech, First-in-Human & PK Studies, Site & Patient Recruitment, and Imaging services.
General information
Firm type
Generalist
Year founded
2011
Location
Region
Europe
Country
Switzerland
City
Liestal
Corporate office
Kasernenstrasse 30, 4410 Liestal, Switzerland
Principals
Franziska Stemmler
Co-founder and CEO
Pascal Winnen
Co-founder and Managing Director EU
Sector focus
Frequently asked questions
How does Hemex source proprietary deal flow?
Hemex sources primarily through its deep integration with the European life-science cluster ecosystem. The firm holds memberships in the Swiss Biotech Association, BioRN, HealthTech Cluster Switzerland, and the BEAM Alliance, giving it early visibility into academic spin-outs and pre-commercial ventures emerging from the Basel-Zurich-Rhine-Neckar corridor. Its collaborative project work with the Swiss Tropical and Public Health Institute provides an additional sourcing channel into global-health innovation.
What investment stage does Hemex typically target?
The firm targets the earliest commercial stages — start-up and early seed — with a focus on ventures that are advancing toward clinical proof-of-concept. Its portfolio companies operate at the intersection of academic research and first regulatory milestones, particularly in diagnostics, medical devices, and novel therapeutic platforms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: